inhibitors may be substantial, not the least due to reduction of inflammatory cytokines and symptomatic improvement, our data adds to increasing evidence that kinase inhibitor monotherapy of malignant disease is not curative, suggesting a need for drug combinations to optimally target the malignant cells.
INTRODUCTION
An activating mutation of JAK2 (JAK2 V617F ) is present in almost all patients with polycythemia vera (PV), 30-50% of patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF) and smaller subsets of patients with other myeloproliferative neoplasms (MPN) [1] [2] [3] [4] [5] . JAK2 V617F is thought to play a critical role in the pathogenesis of these disorders. Consistent with this, a PV-like disease with secondary myelofibrosis arises in mice transplanted with bone marrow expressing JAK2 V617F and mice transgenic for JAK2 V617F develop an ET or PV-like MPN [6] [7] [8] [9] . Based on the success of the BCR-ABL inhibitor, imatinib, for the treatment of chronic myeloid leukemia (CML),
there is considerable interest in the development of small molecule JAK2 kinase inhibitors for the treatment of MPN, and several compounds are currently in clinical trials of myelofibrosis [10] [11] [12] .
Here we describe the in vitro and in vivo activity of CYT387, a specific small molecule inhibitor of wild type and V617F mutant JAK2.
MATERIAL AND METHODS

Expression vectors. For stable cell lines, the retroviral vector MSCV-IRES-GFP (MIG)
was used containing wild-type or V617F alleles of murine JAK2 cDNA (kindly provided by Dr. James Ihle, St. Jude Children's Research Hospital, Memphis, TN) or the murine erythropoietin receptor (EPOR) (kindly provided by Dr. Dwayne Barber, Ontario Cancer Institute, Toronto, Ontario, Canada).
Retrovirus production, cell culture and immunoblotting were performed as described 6 . For details see supplemental information.
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Mutagenesis screen.
The selection for CYT387 resistant clones was performed as described 13 . Details are provided in the supplemental information.
Kinase assays. GST-tagged JAK kinase domains were cloned in Gateway Baculovirus vectors (Inivitrogen) and expressed in SF9 insect cells. The fusion proteins were purified and used in a peptide substrate phosphorylation assay. Assays were performed in 384 well Optiplates using an Alphascreen Protein Tyrosine Kinase P100 detection kit (Perkin Elmer) and a Perkin Elmer Fusion Alpha instrument.
Bone marrow transplantation. Standard techniques were used. All mouse work was performed with approval from the OHSU IACUC. For details see supplemental information.
CYT387 administration. On day 32 after bone marrow transplantation (when all mice
exhibited severe leukocytosis and erythrocytosis) mice were assigned to three groups such that each group had equivalent average body weight and blood counts ( Figure 2 , Supplemental Figure 2A ). CYT387 was dissolved in NMP (120 mg/ml final) (1-methyl-2-pyrrolidinone, Chromasolv® Plus, Sigma). Subsequently, the CYT387/NMP mix was diluted with 0.14M Captisol (Captisol®, Cydex Pharmaceuticals, Inc., Lenexa, KS, USA) to a concentration of 6 mg/ml and further diluted with 0.1M Captisol to a final concentration of 4 mg/ml. All three groups of mice (n=12 per group) were administered CYT387 by oral gavage twice daily at 10-12 hour intervals from day 34 post bone marrow transplant to day 82 (end of experiment). Mice received NMP/Captisol without CYT387 (0 mg/kg group), 25 mg/kg CYT387, or 50 mg/kg CYT387. At day 82 after bone marrow transplantation, all mice were euthanized for analysis except for two mice each from the 50 mg/kg and 25 mg/kg groups, which were taken off CYT387 treatment and
For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From followed for 45 additional days. For assessment of the effects of CYT387 on normal blood counts, naïve Balb/c mice were administered vehicle control, 50 mg/kg, or 100 mg/kg CYT387 in an identical fashion as described above. Peripheral blood was drawn at day 14, 28, 42, and 56 and levels of red cells, white cells, reticulocytes, granulocytes, lymphocytes, and monocytes were analyzed.
Pathological examination. Blood was collected from anesthetized mice by lethal inferior vena cava bleeding. Blood was incubated at 5° C for 2 hours, centrifuged at 4600 rpm for 10 minutes, and serum was stored at -80°C. Organs were dissected and white blood cells from spleen and bone marrow were harvested by passing through a 70µm nylon cell strainer (BD Biosciences, Bedford, MA), followed by red cell lysis.
Histological analysis. Samples from liver, spleen, and humerus were fixed in 3.5 % paraformaldehyde (Protocol®, Kalamazoo, MI) and embedded in paraffin. Sections of 5 µm were stained with hematoxyline/eosin (HE). Decalcified sections of humerus were stained with HE and reticulin stain (American Master*Tech Scientific, Inc. Lodi, CA).
Reticulin stained humerus sections were scored in a blinded fashion on a scale of 0 to 3 for degree of fibrosis with 0 indicating normal tissue and 3 indicating extreme fibrosis 14 
.
Flow cytometry. White cells from bone marrow and spleen were stained with conjugated monoclonal antibodies as described 6 .
Quantitative PCR for GFP (Allele) Burden. Genomic DNA was isolated from mouse splenocytes or Ba/F3 cells and standardized to 10 ng/μl. DNA was amplified with Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen) on an MJ Research Opticon 2 thermal cycler using primers specific for GFP or the genomic mouse GAPDH locus:
For personal use only. Continuous variables were compared by pairwise t-test for two independent samples. Non-linear regression was used to determine a best-fit curve for the GFP qPCR standard curve and generate an r-squared value.
RESULTS
Profiling of a JAK2 inhibitor
CYT387 was discovered by high throughput enzyme and cell-based screening of small molecule libraries, with subsequent optimization of the lead compounds using structureguided medicinal chemistry ( Figure 1A) . Details of the identification process and the results of X-ray diffraction analysis of CYT387 in complex with the kinase domain of JAK2 will be published in a separate manuscript. In vitro kinase assays performed in the presence of 80 μM ATP revealed that CYT387 inhibited the activity of recombinant JAK1, JAK2, JAK3, and TYK2 kinase domains with IC 50 values of 11, 18, 155, and 17 nM, respectively. To globally evaluate specificity, we tested CYT387 against a panel of 128 kinases, using the SelectScreen™ Profiling Service (Invitrogen). Significant activity (defined as an IC 50 < 100nM) was detected against CDK2/cyclin A, MAPK8 (JNK1), PRKCN (PKD3), PRKD1 (PKCμ), ROCK2 and TBK1 (Supplemental Table 1 ).
CYT387 selectively inhibits JAK2-dependent cell lines
We assessed the effects of graded CYT387 concentrations on a panel of cell lines, Figure 1C ).
CYT387 inhibits JAK2 activity and signaling
To determine whether effects of CYT387 on proliferation and apoptosis correlate with inhibition of JAK2 signaling, we exposed Ba/F3 cells expressing JAK2 V617F and EPOR to graded concentrations of CYT387 for 16 hours and analyzed phosphorylation of JAK2 signaling components by immunoblot ( Figure 1D ). While a significant reduction of phospho-JAK2 was evident only at relatively high concentrations of CYT387 (> 2 µM), phosphorylation of ERK1/2 and STAT5 was inhibited at 0.3 µM CYT387 and above .
CYT387 is effective in a murine model of myeloproliferative neoplasms
We next tested whether CYT387 is efficacious in an in vivo model of JAK2 V617F -dependent MPN in which lethally irradiated Balb/c mice are transplanted with bone marrow transduced with a JAK2 V617F retrovirus 6 . Initially, we assessed the overall impact of this compound on the homeostasis of blood cells in naïve mice. We found that CYT387 at twice the dose used in our subsequent disease model (50 and 100 mg/kg) had little to no effect on peripheral blood counts (Supplemental Figure Application of this technique on splenic genomic DNA isolated from mice treated with vehicle or CYT387 showed a high overall level of GFP with a range of 23-90% ( Figure   5B ). Interestingly, we observed a significant reduction in GFP levels (allelic burden) in mice treated with 50 mg/kg CYT387 ( Figure 5C ). These observations suggest that JAK2 .
Effects of CYT387 on plasma cytokines
Patients with myelofibrosis exhibit increased plasma concentrations of inflammatory cytokines, such as IL-6, which are thought to be responsible for the constitutional symptoms that characterize the disease 19 . We therefore hypothesized that responses to (Supplemental table 5 ).
Interestingly, IL-10 and G-CSF concentrations were similar in vehicle-treated diseased mice compared to normal naïve mice. However, IL-10 was significantly down-regulated with CYT387 treatment ( Figure 6E ) and G-CSF was significantly up-regulated compared to normal naïve mice upon treatment with CYT387 ( Figure 6F ). Altogether, these data indicate that mice with JAK2 V617F -induced disease exhibit a complex perturbation of cytokine and chemokine expression that is at least partially normalized by CYT387.
In vitro resistance to CYT387 by overexpression of JAK2
V617F
Resistance to tyrosine kinase inhibitors such as imatinib or dasatinib in CML, or gefitinib in non-small cell lung cancer is frequently due to acquired point mutations in the kinase domain of the target kinases 20, 21 . We have previously shown that resistance mutations 
DISCUSSION
More than 90% of patients with PV and 30-50% of patients with PMF and ET carry the JAK2 V617F allele 22 . Additional patients have activating mutations in exon 12 of JAK2 or in upstream signaling pathways, such as the thrombopoietin receptor (MPL), suggesting that JAK2 activation may be a universal feature of MPN, and as yet unknown mechanisms may be causal in patients without mutations in JAK2 or MPL 23, 24 . Given the In vitro kinase assays revealed CYT387 as a low nanomolar inhibitor of JAK2 JAK1, and TYK2, with very limited off-target effects (Supplemental Table 1 ).
Proliferation of JAK2 V617F cell lines was inhibited by CYT387, with IC 50 values ranging between 500 and 1500 nM ( Figure 2A and Table 2 , as observed by the increase of both early (CD71+) and late (Ter119+) erythroid progenitor cells in the bone marrow (of mice) ( Figure 5C ).
Despite the profound reduction of overall cell numbers, evidenced by the normalization of blood counts and spleen size, the persistence of GFP in the splenic DNA clearly shows that CYT387 fails to eliminate JAK2 V617F expressing cells. Several explanations exist for this observation. First, while high peak levels are achieved, the drug half-life in mice is short, which is insufficient for continuously maintaining plasma concentrations above the IC 50 , even with the 50 mg/kg dose ( Figure 3A ). This may be sufficient for inhibition of proliferation, but insufficient for induction of apoptosis. Second, microenvironmental JAK2-independent signals may promote survival of JAK2 V617F -expressing cells in the presence of CYT387. A third possibility is that the duration of therapy was insufficient and JAK2 V617F expressing cells would continue to decrease with extended duration of treatment.
Significant in vivo activity has also been observed with TG101348, another small molecule inhibitor of JAK2, in a murine model similar to the model used here as well as in xenografts [10] [11] [12] . Since no mice were followed after discontinuation of TG101348, it is unknown whether this compound may induce more durable responses.
However, the data from our mouse model are strikingly similar to early reports from studies of JAK2 inhibitors in patients with advanced myelofibrosis. While these drugs induce a rapid reduction of spleen size in practically all patients, there was an equally rapid recurrence of splenomegaly upon interruption of dosing for toxicity 18 . All in all, these observations suggest that JAK2 inhibitors may be incapable of curing MPN, similar to imatinib's inability to eradicate CML
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. Although this appears to be common to both disease entities, there are also important differences. designed research, analyzed data, contributed valuable reagents, and wrote the paper. WT or Ba/F3-EpoR-JAK2 V617F cells were serum-starved then plated in 6-well plates over a dose gradient of CYT387 for 16 hours at which point cells were lysed and whole cell extracts were subjected to immunoblot analysis using antibodies specific for total or phospho-JAK2, total or phospho-ERK1/2, total or phospho-STAT5, or β-actin. Balb/c mice were subjected to bone marrow transplant with bone marrow donor cells retrovirally-transduced to express JAK2 V617F . Thirty-four days after transplant, mice exhibited symptoms of myeloproliferative neoplasm as measured by elevated white blood cell counts and hematocrit. Mice were divided into three groups and initiated on twice daily oral gavage administration of vehicle control, 25 mg/kg CYT387, or 50 mg/kg CYT387 (n = 12 per group). At day 83 post bone marrow transplant, all mice were sacrificed and representative histologic sections are shown from (A) peripheral blood stained for reticulocytes, (B) spleen stained with hematoxylin and eosin (H&E), (C) Liver (H&E), (D) Bone Marrow (H&E), and (E) Bone marrow (reticulin stain). The left column represents 0mg/kg CYT387, the middle column represents 25mg/kg CYT387, and the right column represents 50 mg/Kg CYT387. Magnification is 10X or 40x for insets. Balb/c mice were subjected to bone marrow transplant with bone marrow donor cells retrovirally-transduced to express JAK2 V617F . Thirty-four days after transplant, mice exhibited symptoms of myeloproliferative neoplasm as measured by elevated white blood cell counts and hematocrit. Mice were divided into three groups and initiated on twice daily oral gavage administration of vehicle control, 25 mg/kg CYT387, or 50 mg/kg CYT387 (n = 12 per group). At day 83 post bone marrow transplant, all mice were sacrificed and genomic DNA was isolated from splenocytes. A quantitative PCR assay was developed to assess the relative level of GFP, normalized to the genomic GAPDH locus. (A) Parental Ba/F3 (GFP-negative) were mixed at varying ratios with Ba/F3-JAK2 V617F cells (GFP-positive). Genomic DNA was isolated and subjected to quantitative PCR using primers specific for GFP or the GAPDH genomic locus. All values were Balb/c mice were subjected to bone marrow transplant with bone marrow donor cells retrovirally-transduced to express JAK2 V617F . Thirty-four days after transplant, mice exhibited symptoms of myeloproliferative neoplasm as measured by elevated white blood cell counts and hematocrit. Mice were divided into three groups and initiated on twice daily oral gavage administration of vehicle control, 25 mg/kg CYT387, or 50 mg/kg CYT387 (n = 12 per group). At day 83 post bone marrow transplant, all mice were sacrificed and serum was harvested from peripheral blood for cytokine analysis with a multiplexed 96-well ELISA based assay. Bar graphs represent mean cytokine levels for V617F were subjected to ENU-mutagenesis in the presence of CYT387. Cells were plated at 2 x 10 5 cells per well of a 96 well plate in media with 4 µM CYT387. Wells were examined every 5 days for colony outgrowth over a 38 day period. Colonies that grew out were expanded and subsequently serum starved overnight in the presence of 4µM CYT387 and subjected to immunoblot analysis using antibodies specific for total or phospho-JAK2 or β-actin. (B) Densitometric analysis of immunoblots in (A). Expression levels for total JAK2 (gray bars) and phospho JAK2 (black bars) were normalized to the levels observed in JAK2 WT cells that are sensitive to CYT387. (C) Genomic DNA was isolated from CYT387-resistant Ba/F3 cells and levels of genomic GFP or GAPDH were assessed by quantitative PCR. A standard curve of varying ratios of GFP-positive/GFP-negative Ba/F3 cell mixtures was included as in Figure 5A . Levels of genomic GFP were normalized as in Figure 5 (normalized first to GAPDH, then to the highest value well on the standard curve) and are presented as percent GFP-positive. Values represent mean ± s.e.m. (n=3).
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